James P. Quinn

James P. Quinn

Auto-generated profile, based on publicly available information

James P. Quinn

Massachusetts General Hospital Department of Neurology, Harvard Medical School, Boston, Massachusetts 02129, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2018 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
JQJames P. Quinn
James P. Quinn
NCNicola J. Corbett
Nicola J. Corbett
KKKatherine Kellett
Katherine Kellett
NHNigel M. Hooper
Nigel M. Hooper
With predictions showing that 131.5 million people worldwide will be living with dementia by 2050, an understanding of the molecular mechanisms underpinning disease is crucial in the hunt for novel therapeutics and for biomarkers to detect disease early and/or monitor disease progression. The metabolism of the microtubule-associated protein tau is altered in different dementias, the so-called tauopathies. Tau detaches from microtubules, aggregates into oligomers and neurofibrillary tangles, which can be secreted from neurons, and spreads through the brain during disease progression. Post-translational modifications exacerbate the production of both oligomeric and soluble forms of tau, with proteolysis by a range of different proteases being a crucial driver. However, the impact of tau proteolysis on disease progression has been overlooked until recently. Studies have highlighted that proteolytic fragments of tau can drive neurodegeneration in a fragment-dependent manner as a result of aggregation and/or transcellular propagation. Proteolytic fragments of tau have been found in the cerebrospinal fluid and plasma of patients with different tauopathies, providing an opportunity to develop these fragments as novel disease progression biomarkers. A range of therapeutic strategies have been proposed to halt the toxicity associated with proteolysis, including reducing protease expression and/or activity, selectively inhibiting protease-substrate interactions, and blocking the action of the resulting fragments. This review highlights the importance of tau proteolysis in the pathogenesis of tauopathies, identifies putative sites during tau fragment-mediated neurodegeneration that could be targeted therapeutically, and discusses the potential use of proteolytic fragments of tau as biomarkers for different tauopathies.

31 July 2018 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
MMMahmoud B. Maina
Mahmoud B. Maina
LBLaura J. Bailey
Laura J. Bailey
SWSherin Wagih
Sherin Wagih
LBLuca Biasetti
Luca Biasetti
SPSaskia J. Pollack
Saskia J. Pollack
LSLouise Serpell
Louise Serpell
Tau is known for its pathological role in neurodegenerative diseases, including Alzheimer’s disease (AD) and other tauopathies. Tau is found in many subcellular compartments such as the cytosol and the nucleus. Although its normal role in microtubule binding is well established, its nuclear role is still unclear. Here, we reveal that tau localises to the nucleolus in undifferentiated and differentiated neuroblastoma cells (SHSY5Y), where it associates with TIP5, a key player in heterochromatin stability and ribosomal DNA (rDNA) transcriptional repression. Immunogold labelling on human brain sample confirms the physiological relevance of this finding by showing tau within the nucleolus colocalises with TIP5. Depletion of tau results in an increase in rDNA transcription with an associated decrease in heterochromatin and DNA methylation, suggesting that under normal conditions tau is involved in silencing of the rDNA. Cellular stress induced by glutamate causes nucleolar stress associated with the redistribution of nucleolar non-phosphorylated tau, in a similar manner to fibrillarin, and nuclear upsurge of phosphorylated tau (Thr231) which doesn’t colocalise with fibrillarin or nucleolar tau. This suggests that stress may impact on different nuclear tau species. In addition to involvement in rDNA transcription, nucleolar non-phosphorylated tau also undergoes stress-induced redistribution similar to many nucleolar proteins.

27 October 2021 in Brain Communications
Verified
Journal Article
Open access
PDF file
JQJames P Quinn
James P Quinn
SKSavannah E Kandigian
Savannah E Kandigian
BTBianca A Trombetta
Bianca A Trombetta
SASteven E Arnold
Steven E Arnold
BCBecky Carlyle
Becky Carlyle
Neurosecretory protein VGF (non-acronymic) belongs to the granin family of neuropeptides. VGF and VGF-derived peptides have been repeatedly identified in well-powered and well-designed multi-omic studies as dysregulated in neurodegenerative and psychiatric diseases. New therapeutics is urgently needed for these devastating and costly diseases, as are new biomarkers to improve disease diagnosis and mechanistic understanding. From a list of 537 genes involved in Alzheimer’s disease pathogenesis, VGF was highlighted by the Accelerating Medicines Partnership in Alzheimer’s disease as the potential therapeutic target of greatest interest. VGF levels are consistently decreased in brain tissue and CSF samples from patients with Alzheimer’s disease compared to controls, and its levels correlate with disease severity and Alzheimer’s disease pathology. In the brain, VGF exists as multiple functional VGF-derived peptides. Full-length human VGF1–615 undergoes proteolytic processing by prohormone convertases and other proteases in the regulated secretory pathway to produce at least 12 active VGF-derived peptides. In cell and animal models, these VGF-derived peptides have been linked to energy balance regulation, neurogenesis, synaptogenesis, learning and memory, and depression-related behaviours throughout development and adulthood. The C-terminal VGF-derived peptides, TLQP-62 (VGF554–615) and TLQP-21 (VGF554–574) have differential effects on Alzheimer’s disease pathogenesis, neuronal and microglial activity, and learning and memory. TLQP-62 activates neuronal cell-surface receptors and regulates long-term hippocampal memory formation. TLQP-62 also prevents immune-mediated memory impairment, depression-like and anxiety-like behaviours in mice. TLQP-21 binds to microglial cell-surface receptors, triggering microglial chemotaxis and phagocytosis. These actions were reported to reduce amyloid-β plaques and decrease neuritic dystrophy in a transgenic mouse model of familial Alzheimer’s disease. Expression differences of VGF-derived peptides have also been associated with frontotemporal lobar dementias, amyotrophic lateral sclerosis, Lewy body diseases, Huntington’s disease, pain, schizophrenia, bipolar disorder, depression and antidepressant response. This review summarizes current knowledge and highlights questions for future investigation regarding the roles of VGF and its dysregulation in neurodegenerative and psychiatric disease. Finally, the potential of VGF and VGF-derived peptides as biomarkers and novel therapeutic targets for neurodegenerative and psychiatric diseases is highlighted.

13 March 2023 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Open access
JQJames P. Quinn
James P. Quinn
EEElizabeth C. Ethier
Elizabeth C. Ethier
ANAngelo Novielli
Angelo Novielli
AMAygul Malone
Aygul Malone
CRChristopher E. Ramirez
Christopher E. Ramirez
BCBecky Carlyle
Becky Carlyle

15 July 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
MGMaya L. Gosztyla
Maya L. Gosztyla
LKLydia Kwong
Lydia Kwong
NMNaomi A. Murray
Naomi A. Murray
CWClaire E. Williams
Claire E. Williams
NBNicholas Behnke
Nicholas Behnke
MYMegan A. Yamoah
Megan A. Yamoah

30 October 2017 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
Illana GozesIllana Gozes
Illana Gozes
GHGünter U. Höglinger
Günter U. Höglinger
JQJames P. Quinn
James P. Quinn
NHNigel M. Hooper
Nigel M. Hooper
KHKina Höglund
Kina Höglund